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Clinical Efficacy of Drug-Eluting
Stents in Diabetic Patients
A Meta-Analysis
Ehtisham Mahmud, MD, FACC, Guilherme Bromberg-Marin, MD,
Vachaspathi Palakodeti, MD, FACC, Lawrence Ang, BS, Dana Creanga, PHD,
Anthony N. DeMaria, MD, MACC
San Diego, California
Objectives The purpose of this study was to compare estimates for revascularization and major adverse cardiac events
(MACE) (death, myocardial infarction, repeat revascularization) in diabetic patients treated with paclitaxel- and
sirolimus-eluting stents (PES and SES).
Background Outcomes in diabetic patients treated with PES and SES have not been adequately evaluated.
Methods We searched MEDLINE/EMBASE from January 2002 to February 2007 and identified abstracts/presentations
from this period at major cardiology conferences. Randomized controlled trials (RCTs) and registries were in-
cluded if data for diabetic patients treated with PES or SES were available. Point estimates with 95% confidence
intervals (CIs) were computed as summary statistics.
Results In RCTs (13 trials; n  2,422) similar point estimates for target lesion revascularization (TLR) (PES: 8.6%, 95%
CI 6.5% to 11.3%; SES: 7.6%, 95% CI 5.8% to 9.9%) and MACE (PES: 15.4%, 95% CI 12.4% to 19.1%; SES:
12.9%, 95% CI 8.5% to 19.2%) were observed. In head-to-head trials (4 RCTs), no difference in the likelihood of
TLR (PES vs. SES) was observed (odds ratio [OR] 1.37, 95% CI 0.64 to 2.9, p  0.42). In registries (16 registries;
n  10,156), point estimates for target vessel revascularization (TVR) (PES: 5.8%, 95% CI 3.9% to 8.5%; SES:
7.2%, 95% CI 4.6% to 11.2%) and MACE (PES: 10.1%, 95% CI 7.3% to 13.8%; SES: 11.9%, 95% CI 8.6% to
16.4%) were also similar. In registries reporting outcomes with both stents (8 registries for TVR and 7 registries
for MACE), the likelihood of TVR (PES vs. SES) (OR 0.77, 95% CI 0.54 to 1.10, p  0.15) and MACE (OR 0.83,
95% CI 0.68 to 1.01, p  0.056) were nonsignificantly lower with PES.
Conclusions This analysis of over 11,000 diabetic patients treated with drug-eluting stents demonstrates single-digit revascu-
larization rates. Furthermore, revascularization and MACE estimates are similar with both PES and SES. (J Am
Coll Cardiol 2008;51:2385–95) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.03.028r
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cpidemiological data have firmly established a relationship
etween coronary heart disease and diabetes mellitus (1).
lthough the precise mechanism behind this relationship
emains uncertain, hyperglycemia, abnormal lipid metabo-
ism, and insulin resistance, coupled with frequently occur-
ing hypertension, result in acceleration of the atheroscle-
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ccepted March 7, 2008.otic process (2). Coronary artery disease is currently
esponsible for three-quarters of diabetes-related deaths (3),
nd as the prevalence of diabetes increases, the number of
iabetic patients requiring revascularization for advanced
oronary artery disease will escalate.
Outcomes with either percutaneous coronary intervention
PCI) or coronary artery bypass graft surgery are poorer for
iabetic than nondiabetic patients (4). Percutaneous coronary
ntervention with bare-metal stents (BMS) was limited in
iabetic patients, owing to higher restenosis rates (5). The
aclitaxel-eluting stent (PES) Taxus (Boston Scientific,
atick, Massachusetts) and the sirolimus-eluting stent (SES)
ypher (Johnson & Johnson, Miami Lakes, Florida) are both
ffective in reducing the need for repeat revascularization
ompared with BMS (6–12), and this has led to PCI being
sedmore frequently in diabetic patients (13,14). However, the
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DES in Diabetic Patients June 24, 2008:2385–95use of DES in diabetic patients is
considered off label by the Food
and Drug Administration, because
adequate numbers of diabetic pa-
tients have not been evaluated in
clinical trials (15,16). Further-
more, data regarding the relative
efficacy of the 2 stents in diabetic
patients are less clear. There has
only been 1 randomized controlled
trial (RCT) comparing the 2 stents
exclusively in diabetic patients, and
this study included only 125 pa-
tients in each arm and also did not
have a clinical end point (17). Be-
cause late luminal loss is greater
with the PES than the SES (6,12),
it could be hypothesized that dia-
betic patients, who have a higher
proclivity to restenosis, would have
worse clinical outcomes with the
PES. However, an attenuation of
he antimigratory effect of sirolimus described in the presence
f hyperglycemia (18) could lead to lower efficacy of SES in
iabetic patients. In addition, the variability in stent platforms,
olymer technology, and delivery systems could also lead to
ifferences in clinical outcomes between the 2 stents.
The evaluation of diabetic patients treated with PES
nd SES in multiple RCTs and registries provides an
pportunity to determine clinical outcomes of DES in
iabetic patients and to compare the relative efficacy and
afety of these 2 DES. With suggested guidelines (19),
his meta-analysis was performed to estimate target
esion revascularization (TLR), major adverse cardiac
vents (MACE), and stent thrombosis, for diabetic
atients receiving either PES or SES as part of an RCT
nd to compare the efficacy of the 2 DES from head-to-
ead RCTs. With registry data, we also estimated target
essel revascularization (TVR) and MACE for diabetic
atients receiving either DES. Comparison of the 2 DES
rom registries that reported outcomes with both stents in
imilar populations was also separately performed. Be-
ause angiographic measures, such as binary restenosis
nd late loss, are debatable end points for clinical utility
n individual patients and are not available for most
egistries, we specifically chose not to include them in
his analysis.
ethods
dentification and selection of studies. A search was
onducted of the English language published reports in
EDLINE and EMBASE from January 2002 to February
007. Abstracts and presentations from this time period at
ajor international cardiology conferences (American Col-
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
MACE  major adverse
cardiac event
OR  odds ratio
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
RCT  randomized
controlled trial
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularization
TVR  target vessel
revascularizationege of Cardiology, American Heart Association, Europeanociety of Cardiology, Transcatheter Cardiovascular Ther-
peutics, and Paris Course on Revascularization) were also
eviewed. The search terms “drug,” “eluting,” and “stent”
ere combined with the terms “registry” or “registries” and
hen “clinical” and “trial” or “trials” as 2 distinct published
eport searches. The RCTs and registries were included in
he analysis if data for diabetic patients treated with a PES
r SES were available for at least 1 of the clinical end points
TLR or MACE for RCTs; TVR or MACE for registries)
eing assessed and were not duplicative. Target lesion
evascularization was defined as any procedure (PCI or
oronary artery bypass graft surgery) performed to revascu-
arize the index lesion, whereas TVR was defined as any
rocedure to revascularize the index vessel. Although the
efinition of MACE varied slightly in the various studies, it
sually consisted of cardiac death, myocardial infarction,
nd repeat revascularization.
CTS. All studies and abstracts/presentations were identi-
ed and reviewed by at least 2 of the authors. The RCTs
Figure 1 Clinical Event Rates for Diabetic
Patients Treated With DES in RCTs
Point estimates for target lesion revascularization and major adverse cardiac
events for diabetic patients treated with drug-eluting stents (DES) in (A) all ran-
domized controlled trials (RCTs) and (B) RCTs with Silber score 5. Bars indi-
cate 95% confidence intervals.
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June 24, 2008:2385–95 DES in Diabetic Patientsere only included in the analysis if they involved de novo
oronary lesions, the methodology and results of the trial
ad been published, and data for the diabetic subset were
vailable. Published data were always given priority, and if
he data were unavailable for the diabetic cohort, the
rincipal investigator was contacted and asked to provide
he necessary information. There were no numerical limi-
ations regarding trial size for study inclusion. A method of
ssessing the quality of clinical trials, including RCTs with
ES, has been proposed (20), adhering to the principles of
vidence-based medicine. The Silber score evaluates various
actors that constitute a well-designed RCT, including
dequate power, being multicenter, having an independent
vents committee, and having a primary clinical end point.
igh scores (closer to 10) suggest a stronger basis for
aking an evidence-based decision, whereas low scores
closer to 0) provide hypotheses rather than confirmatory
vidence. A Silber score was assigned to all of the RCTs.
EGISTRIES. All registries with prospectively collected out-
omes data after the use of either the PES or SES were
dentified. Registries were included if data for at least 1 of
he end points (TVR or MACE) for diabetic patients could
e extracted from the published manuscript or from ab-
tracts/presentations. In addition, registries that were not
ublished in complete form were also analyzed separately.
tatistical methodology. All analyses were conducted on
he basis of the intent-to-treat principle. Point estimates
nd 95% confidence intervals (CIs) were computed for all
utcomes as summary statistics with both random effects
Der Simmonian and Laird method) (21) and fixed effects
odels (chi-square with normal approximation) (22). The
ull hypothesis of homogeneity of response across studies
as tested with the Cochran Q statistic. If the null hypoth-
sis was rejected, point estimates and 95% CI estimated on
he basis of a random effects model were presented. Other-
ise, the fixed effects solution was presented. All of the
oint estimates and comparative analyses from the head-to-
Figure 2 Comparative Analysis of Target Lesion Revascularizat
With Drug-Eluting Stents in Diabetic Patients From He
Likelihood of target lesion revascularization (paclitaxel-eluting stent [PES] vs. siroli
contribution of each trial. See Table 1 for further details regarding the individual tr
Angiographic Results: Do Diabetic Patients Derive Similar Benefit from Paclitaxel-E
2006; REALITY  Sirolimus- vs Paclitaxel-Eluting Stents in De Novo Coronary Arter
Revascularization trial; TAXi  A Prospective Randomized Comparison Between Paead RCTs and registries are based on the random effectsolution. The only outcomes presented with the fixed effects
olution to derive point estimates and 95% CI are for TLR
nd MACE for each DES from the RCTs. Because stent
hrombosis was a low-incident event, the estimated rate and
5% CIs in the analysis are based on the observed data and
epresent raw percentages computed as the number of
eported stent thromboses out of the total diabetic cohort.
tatistical analyses were performed with the Comprehensive
eta-analysis software, version 2.0 (Biostat Inc., Engle-
ood, New Jersey). The results presented in this analysis are
ased primarily on studies that do not evaluate both PES
nd SES in the same population. Given the diversity of the
opulations and the differences between RCT and registry
ata, a direct head-to-head statistical comparison was not
ursued for the entire dataset. However, a comparative
nalysis is presented for TLR from a subset of head-to-head
-Head Randomized Controlled Trials
luting stent [SES]) (n  899 diabetic patients). Size of boxes indicates relative
cluded. CI  confidence interval; ISAR-DIABETES  Intracoronary Stenting and
and Sirolimus-Eluting Stents trial; pc  personal communication from J. J. Goy,
ns trial; SIRTAX  Sirolimus-eluting and Paclitaxel-eluting Stents for Coronary
l and Sirolimus Eluting Stents in the Real World of Interventional Cardiology trial.
Figure 3 Clinical Event Rates for Diabetic Patients
Treated With Drug-Eluting Stents in Registries
Point estimates for target vessel revascularization and major adverse cardiac
events for diabetic patients treated with drug-eluting stents in all registries.
Bars indicate 95% confidence intervals.ion
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DES in Diabetic Patients June 24, 2008:2385–95CTs in which the 2 stents were compared. Similarly, a
omparative analysis of TVR and MACE from a subset of
egistries that reported outcomes with both DES in similar
opulations is also presented.
esults
CTs. There were 13 RCTs that met the inclusion criteria
n which 2,422 diabetic patients were enrolled (Table 1). Of
hese 13 studies, 4 involved a direct head-to-head compar-
son of the PES and SES (17,23–25), of which only 1 was
multicenter trial (25). The ISAR-DIABETES trial (In-
racoronary Stenting and Angiographic Results: Do Dia-
etic Patients Derive Similar Benefit from Paclitaxel-
luting and Sirolimus-Eluting Stents) was a 2-center study
nd is the only trial exclusively conducted in diabetic
atients (n  250) with a direct head-to-head comparison
f the 2 DES (17). The TAXi (A Prospective Randomized
omparison Between Paclitaxel and Sirolimus Eluting
tents in the Real World of Interventional Cardiology) trial
as a single center comparison between the 2 stents in
hich one-third of the patients were diabetic (n  69) (23)
J. J. Goy, personal communication, 2006). The SIRTAX
Sirolimus-eluting and Paclitaxel-eluting Stents for Coro-
andomized Controlled Trials Included in the Meta-Analysis
Table 1 Randomized Controlled Trials Included in the Meta-Ana
Study Summary Study Site Tota
ISAR-Diabetes (17) SES vs. PES comparison
at 2 centers
Munich,
Germany
125
TAXi (23), J. J. Goy, personal
communication, 2006
SES vs. PES comparison
at single center
Lausanne,
Switzerland
102
SIRTAX (24,26) SES vs. PES comparison
at 2 centers
Bern,
Switzerland
503
REALITY (25,26) SES vs. PES comparison
at multiple centers
Global 684
SIRIUS (6) SES vs. BMS comparison
at multiple centers
U.S. 533
5
DIABETES (28) SES vs. BMS comparison
at multiple centers
Spain 80 S
8
SES-SMART (29) SES vs. BMS comparison
at multiple centers
Italy 129
1
RAVEL (30) SES vs. BMS comparison
at multiple centers
Europe 120
1
TAXUS II (31,32) PES§ vs. BMS
comparison at
multiple centers
Europe 266
2
TAXUS IV (13) PES vs. BMS comparison
at multiple centers
U.S. 662
6
TAXUS V (33,34) PES vs. BMS comparison
at multiple centers
U.S. 577
5
TAXUS VI (35) PES vs. BMS comparison
at multiple centers
Europe 219
2
ISAR-Test (27), A. Kastrati,
personal communication,
2006
PES vs. SCS at single
center
Munich,
Germany
225
Follow-up time is reported for target lesion revascularization (TLR) (follow-up for other outcomes
iabetic patients only; §results and demographic data represent a combination of both the mode
BMS  bare-metal stent; MACE  major adverse cardiac events; SES  sirolimus-eluting stentary Revascularization) trial, was a 2-center study that (ompared outcomes between these 2 DES with a primary
linical end point and enrolled approximately 20% diabetic
atients (n  201) (24,26). The REALITY (Sirolimus- vs.
aclitaxel-Eluting Stents in De Novo Coronary Lesions)
rial is the only multicenter clinical trial conducted to
ompare the 2 DES and enrolled 28% diabetic patients (n
79) (25,26). The limitations of the 4 aforementioned
ead-to-head trials include: a small number of centers
17,23,24), absence of an independent core laboratory
17,23,24), an inability to angiographically blind the inves-
igators to the stent placed (17,23–25), and the use of
ngiographic primary end points (17,25). In the evaluation
f these trials with the Silber score, all 4 trials were assigned
ower Silber score values than the pivotal RCTs of these
ES versus their BMS controls (6,12). In the other 9
CTs, PES or SES were compared against their BMS
ontrol group, except for the ISAR-TEST (Intracoronary
tenting and Restenosis-Test Equivalence Between 2
rug-Eluting Stents) in which a PES (26% diabetic pa-
ients; n  58) was compared against a BMS coated on-site
ith nonpolymeric rapamycin (not SES Cypher) (27) (A.
astrati, personal communication, 2006). The 4 SES trials
ere all multicenter and included the pivotal SIRIUS
nts (n)
Mean Age (Mean  SD) Gender (% Male)
Follow-Up*
(Months)PES SES PES SES
25 PES 68.3 9.6‡ 67.7 10.2‡ 71.2‡ 74.4‡ 9
00 PES 63 10 65 10 83.0 77.5 12
09 PES 62 12 62 11 78.4 75.9 12
69 PES 62.6 10.0 62.6 10.5 72.0 74.1 12
S
— 62.1 11.2 — 72.6 12
— 65.9 9.0‡ — 62.5‡ 9
S
— 66 11‡ — 69.0‡ 8
S
— 64.2 9.3‡ — 68.4‡ 12
S
61.5 10.5 SR
59.3 10.1 MR
— 70 SR
76 MR
— 12
S
62.6 10.3‡ — 59.4‡ — 12
S
62.9 11.2 — 70.2 — 9
S
61.8 9.7 — 76.3 — 9
25 SCS 66.6 10.2 66.8 10.5 78.7 75.1 9
vary); †percent and actual count of events where reported; ‡baseline characteristics reported for
R) and slow-release (SR) paclitaxel-eluting stent (PES) formulations.
sirolimus-coated stent.lysis
l Patie
SES, 1
SES, 1
SES, 5
SES, 6
SES,
25 BM
ES,
0 BMS
SES,
28 BM
SES,
18 BM
PES,
70 BM
PES,
52 BM
PES,
79 BM
PES,
27 BM
PES, 2
mightSirolimus-eluting Balloon-Expandable Stent in the Treat-
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June 24, 2008:2385–95 DES in Diabetic Patientsent of Patients with De Novo Native Coronary Artery
esions) trial (6,28–30) but only 1 trial that exclusively
nrolled diabetic patients (n  160) (28). The 4 PES trials
ere also all multicenter and included the pivotal Taxus IV
tudy (13) in addition to the Taxus V and VI trials, which
nrolled increasingly complex lesions and patients (31–35).
Clinical follow-up was obtained in all studies at 8 to 12
onths, whereas angiographic follow-up was obtained in
75% of patients in all studies except the SIRTAX (53.4%
ngiographic follow-up) and TAXi trials (no angiographic
valuation mandated). Many published sources only pro-
ided patient age and gender for the entire population
diabetic and nondiabetic), but when diabetic patient infor-
ation was provided (13,17,28–30) no differences in age or
ender were noted. The definition of MACE (cardiac
eath, myocardial infarction, ischemia driven TLR or TVR)
as reasonably homogenous across the trials. However,
ubtle variations in the definition included all cause mortal-
ty and documented stent thrombosis or occlusion in the
AXi and ISAR-TEST trials as additional MACE end
oints (23,27). Three trials did not require revascularization
o be ischemia driven (28,30,31). Data concerning stent
hrombosis were only available for 8 studies (13,17,24–
ontinued
Table 1 Continued
Silber
Score (24)
(0–10) Diabetic Patients (n)
TLR†, % (n/N)
PES SES
4 125 SES, 125 PES 12.0 (15/125) 6.4 (8/1
5 33 SES, 36 PES 2.8 (1/36) 3.0 (1/3
6 108 SES, 93 PES 12.9 5.6
4 187 SES, 192 PES 5.2 8.1
10 131 SES, 148 BMS — 6.9
7 80 SES, 80 BMS — 7.3
6 29 SES, 45 BMS — 17.2 (5/2
7 19 SES, 25 BMS — 0.0 (0/1
7 32 PES, 40 BMS 3.1 (1/32) —
10 155 PES, 163 BMS 7.4 —
9 183 PES, 173 BMS 9.6 (17/178) —
10 39 PES, 50 BMS 2.6 (1/39) —
4 58 PES, 73 SCS 10.3 (6/58) —6,28–30,33,34) and were based on reported events similar ao those in “real world” studies (36) and before the use of the
ecently agreed upon Academic Research Consortium def-
nition of stent thrombosis (37). Dual antiplatelet therapy
ith aspirin and a thienopyridine was routinely recom-
ended for at least 6 months after the placement of a PES
nd for at least 2 to 3 months after the placement of an SES
n the various trials.
egistries. There were 16 registries involving 10,156 dia-
etic patients (PES 5,597; SES 4,559) that met the inclu-
ion criteria and were included in this meta-analysis (Table
) (38–53). Six of these registries have been published in
omplete form (38,39,42,45,47,49), whereas data from the
ther 10 are derived from published abstracts and presen-
ations. The majority of registries (10 studies) (40,41,43,
6,48–53) were multicenter, whereas data from 8 registries
38–45) were comparative between the 2 DES. Follow-up
as between 6 and 12 months after the index procedure,
nd the major clinical outcomes of TVR and MACE
death, myocardial infarction, and TVR) were available for
ost studies. To maintain consistency, when MACE events
ere reported separately as TLR-MACE and TVR-
ACE, we chose to report and include only TVR-MACE
n the analysis. Patient age and gender data were only
MACE†, % (n/N)
Stent Thrombosis at 8–12
Months Follow-Up, % (n/N)
PES SES PES SES
— — 0.8 (1/125) 0.0 (0/125)
5.6 (2/36) 9.1 (3/33) — —
— — 2.2 (2/93) 0.0 (0/108)
— — 3.1 (6/192) 1.1 (2/187)
— — — —
— 11.3 — 0.0 (0/80)
— 20.7 (6/29) — 3.4 (1/29)
— 10.5 (2/19) — 0.0 (0/19)
15.6 (5/32) — — —
15.6 — 0.6 —
16.9 (30/178) — 0.6 (1/177) —
— — — —
13.8 (8/58) — — —25)
3)
9)
9)vailable for the diabetic patients from 9 registries (39–
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DES in Diabetic Patients June 24, 2008:2385–952,44,45,47,49,50). With the exception of ARTS II (Arte-
ial Revascularization Therapy Study II) (49), which was a
egistry-controlled trial, all of the other registries reported
real-world” experience that included evaluation of DES in
imple and complex lesions during single and multivessel
CI. Mandatory angiographic follow-up was only required
n 4 registries (46,47,49,50), and therefore the majority of
utcomes events were clinically driven. Dual antiplatelet
herapy with aspirin and a thienopyridine was routinely
ecommended for at least 6 months after the placement of a
ES and for at least 3 months after the placement of an SES.
ooled analysis. The pooled analysis of the RCTs yields
stimated rates of TLR (PES: 8.6%, 95% CI 6.5% to 11.3%;
ES: 7.6%, 95% CI 5.8% to 9.9%) and MACE (PES:
5.4%, 95% CI 12.4% to 19.1%; SES: 12.9%, 95% CI 8.5%
o 19.2%) in diabetic patients that were similar for both
ES with overlapping CIs for the respective point estimates
Table 3) (Fig. 1A). The estimated rates of stent thrombosis
PES: 1.48%, 95% CI 0.74% to 2.63%; SES: 0.55%, 95% CI
.11% to 1.59%) were low for both stents. Because studies
ith lower Silber scores more often generate hypotheses
han resolve questions (20), we repeated the analysis for
atients enrolled in trials with a Silber score 5, which
esulted in exclusion of 4 studies (17,23,25,27). In the
tudies with higher Silber scores (6,13,24,28–36), the esti-
egistries Included in Meta-Analysis
Table 2 Registries Included in Meta-Analysis
Study Summary Stu
Cosgrave et al. (38) SES vs. PES comparison at
1 center
Milan, I
RESEARCH/T-SEARCH (39) SES vs. PES comparison at
1 center
Rotterd
the N
SOLACI (40) SES vs. PES comparison at
20 centers
Latin Am
STENT (all) (41) SES vs. PES comparison at
8 centers
U.S.
C vs. T REWARDS (42) SES vs. PES comparison at
1 center
Washin
DC
TC-WYRE (43) SES vs. PES comparison at
19 centers
U.S.
Prairie Institute (44) SES vs. PES comparison at
1 center
Springfi
Illino
Stankovic et al. (45) SES vs. PES comparison at
2 centers
Italy
SIRIUS-DIRECT (46) SES direct stenting at
16 centers
U.S.
Berenguer et al. (47) SES experience at 1 center Spain
German Cypher-Stent
Registry (48)
SES experience at 376 centers German
ARTS II (49) SES experience at 45 centers Europe
PORTO I (50) SES experience at 9 centers Portuga
MILESTONE II (51) PES experience at 164 centers Global
ARRIVE 1 (52,53) PES experience at 50 centers U.S.
ARRIVE 2 (53) PES experience at 53 centers U.S.
Follow-up time is reported for target vessel revascularization (TVR) (follow-up for other outcomes
iabetic patients only; §estimates based on the reported demographic data for insulin- and non–i
MACE  major adverse cardiac events; SES  sirolimus-eluting stent; PES  paclitaxel-elutingated rates of TLR (PES: 8.9%, 95% CI 6.2% to 12.6%; tES: 8.0%, 95% CI 5.4% to 11.6%), MACE (PES: 16.2%,
5% CI 12.8% to 20.4%; SES: 13.8%, 95% CI 8.7% to
1.0%), and stent thrombosis (PES: 1.23%, 95% CI 0.34%
o 3.12%; SES: 0.42%, 95% CI 0.01% to 2.34%) were also
imilar for both DES (Table 3) (Fig. 1B). A head-to-head
omparison of TLR from the 4 RCTs (17,24–27) (A.
astrati, J. J. Goy, personal communication, 2006) that
nrolled diabetic patients treated with both DES revealed
o difference in the likelihood of requiring revascularization
ith either stent in diabetic patients (PES vs. SES; odds
atio [OR] 1.37, 95% CI 0.64 to 2.9, p  0.42) (Fig. 2).
When evaluating the registries, the point estimates for
VR (PES: 5.8%, 95% CI 3.8% to 8.5%; SES: 7.2%, 95%
I 4.6% to 11.2%) and MACE (PES: 10.1%, 95% CI 7.3%
o 13.8%; SES: 11.9%, 95% CI 8.6% to 16.4%) showed
imilar and low rates for both DES (Table 3) (Fig. 3).
ecause all of the registries had not appeared in a peer-
eviewed journal at the time of this study, the analysis was
epeated separately for those published and revealed a
imilar rate of TVR and MACE with both stents, although
he absolute event rates in the published studies were higher
Table 3). Eight registries (38–45) reported outcomes of
VR with both stents in similar populations, whereas 7
egistries (38–42,44,45) reported outcomes of MACE with
oth stents in similar populations. A comparative analysis of
e
Total
Patients (n)
Mean Age (Mean  SD)
PES SES
248 SES, 281 PES 62.3 9.9 62.1 11.5
ands
145 SES, 148 PES 64.6 10.3‡ 62.6 10.2‡
353 SES, 280 PES 59.3 7.9‡ 60.2 6.0‡
3,421 SES, 3,142 PES 63.5§ 63.3§
873 SES, 447 PES 65.8 17.9‡ 64.3 14.5‡
742 SES, 816 PES 64.7 11.4 64.1 11.9
954 SES, 208 PES 65.8 11.1‡ 66.4 11.2‡
147 SES, 113 PES 63 9‡ 65 9‡
225 SES — 62.5 12.2
231 SES — 65‡
5,878 SES — 63.8
159 SES — 64.5 8.7‡
120 SES — 65.0 9.8‡
3,688 PES 60.7 11.3 —
2,585 PES 63.9 11.5 —
5,007 PES 64.5 11.8 —
vary); †percent and actual count of events where reported; ‡baseline characteristics reported for
ependent diabetic patients.dy Sit
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June 24, 2008:2385–95 DES in Diabetic Patients.77, 95% CI 0.54 to 1.10, p 0.15) (Fig. 4A) and MACE
PES vs. SES; OR 0.83, 95% CI 0.68 to 1.01, p  0.056)
Fig. 4B) to be nonsignificantly lower with the PES.
iscussion
his report of over 12,000 diabetic patients is the largest
tudy evaluating outcomes of DES in diabetic patients and
rovides a number of important findings. This meta-
nalysis demonstrates that DES are highly effective in
educing the need for repeat revascularization in diabetic
atients, decreasing the incidence to single digits. More-
ontinued
Table 2 Continued
Gender (% male)
Follow-Up*
(Months)
Diabetic
Patients (n)PES SES
86.8 89.1 9 60 SES, 67 PES 19
67‡ 66‡ 12 145 SES, 148 PES
66.3‡ 65.4‡ 12 353 SES, 280 PES
59.1§ 60.1§ 9 875 SES, 805 PES 4
63.7 57.2 6 873 SES, 447 PES
64.7 68.5 12 247 SES, 289 PES
58.2‡ 59.3‡ 12 954 SES, 208 PES
82.3‡ 84.4‡ 9 147 SES, 113 PES 18
— 69.3 6 70 SES
— 62.2‡ 12 98 SES
— 75.1 7 458 SES
— 66.7‡ 12 159 SES
— 60.0‡ 6 120 SES
77.3 — 12 1,254 PES 6
68 — 12 750 PES 5
66.9 — 6 1,236 PES
esults of Pooled Analysis With Point Estimates for Clinical Events
Table 3 Results of Pooled Analysis With Point Estimates for Cl
Revascularization,*† % (95% CI)
PES SES
RCTs (13,17,23–37) 8.6 (6.5–11.3) 7.6 (5.8–9.9) 1
RCTs with Silber score 5
(13,24,26,28–37)
8.9 (6.2–12.6) 8.0 (5.4–11.6) 1
Registries (40–56) 5.8 (3.9–8.5) 7.2 (4.6–11.2) 1
Registries (published)
(40,41,44,45,48,50,52)
10.5 (5.0–20.8) 10.5 (3.8–25.7) 1
Registries (presented)
(42,43,46,47,49,51,53–56)
4.2 (3.0–6.0) 5.7 (4.0–8.0)
Point estimates; †target lesion revascularization (TLR) for randomized controlled trials (RCTs) an
CI  confidence interval; MACE  major adverse cardiac events (death, myocardial infarction
ES  sirolimus-eluting stent.ver, in addition to the results obtained in pivotal RCTs of
ES, these results are also seen in high-risk “real world”
opulations. Furthermore, this analysis represents the most
omprehensive and definitive data showing that the rates of
epeat revascularization, MACE, and stent thrombosis are
imilar for PES and SES. The data also demonstrate that
hort-term stent thrombosis rates with both DES are low in
iabetic patients and comparable to those reported for
nselected populations (54).
Diabetic patients are predisposed to more aggressive
therosclerosis and are at high risk for restenosis (1–5).
TVR†, % (n/N) MACE†, % (n/N)
ES SES PES SES
/67) 33.3 (20/60) 23.9 (16/67) 36.7 (22/60)
.9 10.3 15.6 20.4
.0 5.7 5.8 9.1
/805) 3.4 (30/875) 6.8 (55/805) 7.1 (62/875)
/221) 3 (19/630) 12 (27/221) 11 (69/630)
.8 8.5 — —
.9 6.4 12.1 15.1
/113) 23.1 (34/147) 19.5 (22/113) 24.5 (36/147)
2.9 — 4.3
— — 12.2 (12/98)
9.8 (45/458) — —
3.8 — 4.4
2.5 (3/120) — 5.0 (6/120)
/1,098) — 9.4 (103/1,098) —
/750) — 8.4 (63/750) —
.9 — 3.3 —
CTs and Registries
l Events in RCTs and Registries
MACE,* % (95% CI) Stent Thrombosis,‡ % (95% CI)
ES SES PES SES
2.4–19.1) 12.9 (8.5–19.2) 1.48 (0.74–2.63) 0.55 (0.11–1.59)
2.8–20.4) 13.8 (8.7–21.0) 1.23 (0.34–3.12) 0.42 (0.01–2.34)
.3–13.8) 11.9 (8.6–16.4) NA NA
2.7–22.2) 15.9 (9.6–25.3) NA NA
.1–9.9) 8.2 (5.1–12.8) NA NA
t vessel revascularization (TVR) for registries; ‡actual event rates.
arget lesion revascularization or target vessel revascularization); PES  paclitaxel-eluting stent;P
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DES in Diabetic Patients June 24, 2008:2385–95hey usually have smaller vessels and longer lesions, which
re additional predictors of restenosis (2–5). Despite these
acts, this analysis demonstrates that single-digit rates of
epeat revascularization can be achieved in diabetic patients
ith DES, which represents a significant improvement over
he 20% to 40% rate of repeat revascularization previously
een with BMS (6,12,28,30). Importantly, low revascular-
zation rates were observed not only in RCTs, which
ypically include selected and lower-risk individuals, but also
n registries, which include a much broader patient popula-
ion and lesion subset.
Surprisingly, the estimated rate of repeat intervention in
iabetic patients from registry data (TVR: PES 5.8%, SES
.2%) was lower than the rate from the RCTs (TLR: PES
.6%, SES 7.6%), despite including reintervention for any
esion in the treated artery. However, this is consistent with
revious studies that have demonstrated a higher reinter-
ention rate in RCTs with mandated angiographic
ollow-up (55), whereas reintervention is usually symptom-
riven in registries. Therefore, even though registries typi-
ally include more higher-risk patients than are usually
nrolled in RCTs, the actual rate of revascularization is
ften lower (2).
The current analysis demonstrates that in diabetic pa-
ients the estimated rates of TLR, TVR, and MACE are
imilar for patients receiving a PES or an SES (Figs. 1 to 4).
Figure 4 Comparative Analysis of Clinical Events for Diabetic P
With Drug-Eluting Stents in Registries Enrolling Simila
(A) Likelihood of target vessel revascularization (PES vs. SES) (n  5,542 diabetic
diabetic patients). Size of boxes indicates relative contribution of each study. See
try Experience at the Washington Hospital Center With Drug-Eluting Stents; RESEA
ogy Hospital registries; SOLACI  Society of Latin American Interventional Cardiolo
REWARDS  Taxus Registry Experience at the Washington Hospital Center With D
study; other abbreviations as in Figure 2.hese data do not confirm the results of a single study dnvolving 2 centers (17) that suggested a difference in
linical outcomes between PES and SES in diabetic pa-
ients. The analysis was repeated for multicenter RCTs with
Silber score exceeding 5 (20), to ensure that data were
eliable and in adherence with the principles of evidence-
ased medicine. This revealed that the numerical differences
n TLR and MACE rates between PES and SES were even
ess pronounced in these studies (Fig. 1B). Rates of MACE
nd stent thrombosis with either DES were also considered
omparable to those previously reported for nondiabetic
atients (56).
Analysis of the 4 RCTs that reported a head-to-head
omparison of PES and SES also demonstrated no differ-
nce in the rate of repeat revascularization between the 2
tents. These data provide the strongest evidence that any
ifference that might exist in late loss or binary restenosis
etween these 2 stents does not play a clinically meaningful
ole in the treatment of diabetic patients. These findings
ontrast with the results of a previous meta-analysis, not
imited to diabetic patients, in which the TLR rate in
opulations was lower in patients treated with SES (5.1%)
ompared with PES (7.8%) (OR 0.64; 95% CI 0.49 to
.84; p  0.001) (54). Because late lumen loss and the
egree of neointimal tissue formation is greater with PES
ompared with SES (2,6,54), one might have expected
linically significant differences in revascularization rates in
ts Treated
ulations
nts). (B) Likelihood of major adverse cardiac events (PES vs. SES) (n  5,006
2 for further details regarding registries included. C REWARDS  Cypher Regis-
-SEARCH  Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiol-
registry; STENT  Strategic Transcatheter Evaluation of New Therapies group; T
ting Stents; TC-WYRE  The Taxus Cypher “What’s Your Real-World Experience”atien
r Pop
patie
Table
RCH/T
gists
rug-Eluiabetic patients with the 2 stents. Our findings might be
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June 24, 2008:2385–95 DES in Diabetic Patientsue to a difference in the mechanism of action of paclitaxel
nd sirolimus in diabetic patients. Both drugs act by
educing smooth muscle cell proliferation, which is central
o the development of neointimal hyperplasia and resteno-
is, through inhibition of the cell cycle. Sirolimus induces
1 cell cycle inhibition, whereas paclitaxel predominantly
eads to M-phase arrest (57). Smooth muscle cell cultures
ave been used to compare the activities of sirolimus and
aclitaxel in a model of diabetes. Although both drugs
ctivate mitogen-activated protein kinase pathways simi-
arly, sirolimus potently activates AKT-dependent signal-
ng, overriding the down-regulation of this pathway by
nsulin resistance. This effect is associated with attenuation
f the antimigratory effects of sirolimus in the presence of
yperglycemia, which might account for decreased efficacy
n diabetic patients as opposed to nondiabetic patients (18).
wo-year outcomes for diabetic patients treated with PES
r SES available from 1 single-center registry are consistent
ith this hypothesis, because TVR at 2 years was numeri-
ally lower for diabetic patients treated with PES (9.7%
ES vs. 15.3% SES, p 0.06) (58). However, the results of
ur comparative analysis of TVR and MACE from regis-
ries reporting outcomes with both DES did not demon-
trate a significant difference between the 2 DES (Fig. 4).
The occurrence of late stent thrombosis with DES is an
ncreasingly important topic. Several pathological studies
ave shown that neointimal coverage might be incomplete 3
o 6 months after DES implantation, and this has been
ssociated with subclinical thrombus formation (59). The
isk of stent thrombosis might be even greater in diabetic
atients. In a porcine model, uncontrolled hyperglycemia
esulted in increased thrombosis after coronary stent place-
ent (60), and diabetes has also been associated with a
igher rate of late stent thrombosis (36). In this meta-
nalysis, the reported rates of short-term stent thrombosis
or both DES were low (PES 1.48%; SES 0.55%) and
imilar to those previously reported for mixed diabetic and
ondiabetic populations (PES 1.1%, SES 0.9%) (54). How-
ver, these results should be interpreted with caution, given
he small number of events reported, the nonuniform
efinitions used, and the intermediate follow-up period of 6
o 12 months in the studies included in this analysis.
tudy limitations. Owing to the differences in angio-
raphic appearance of PES and SES, it is impossible to
dequately blind observers to the 2 stents. All studies
ere open label in design and therefore might have been
ubject to observer bias. Because data were collected from
variety of studies, the length of follow-up varied and
aseline data were heterogenous. Use of the random
ffects model should help overcome some of these limi-
ations. Furthermore, data from registries are nonran-
omized and suffer from selection bias. We did not
nclude studies evaluating newer DES, because interme-
iate and long-term outcomes with these stents are not
et available. Owing to the low number of events,
onuniform definitions, and the absence of long-termollow-up, this study is unable to definitively address the
ssue of late stent thrombosis with DES in diabetic
atients. Whereas individual patient data are preferred
or any analysis, in the absence of access to such data,
linical inferences based on summarized results are infor-
ative. With over 12,000 diabetic patients (over 11,000
reated with DES) in this analysis, we believe reliable
onclusions can be drawn regarding similar clinical out-
omes with both PES and SES in diabetic patients.
onclusions
his meta-analysis demonstrates that DES are associated
ith single-digit repeat revascularization rates in diabetic
atients. No differences in clinical outcomes with the use of
ES or SES were observed in these patients.
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